Calidi Biotherapeutics Streamlines Board, Enhances Audit Oversight

Calidi Biotherapeutics ( (CLDI) ) has issued an update.

On March 29, 2026, Calidi Biotherapeutics director Allan J. Camaisa notified the board’s Nominating and Corporate Governance Committee that he will allow his term to expire at the company’s 2026 annual stockholder meeting, with no disagreements cited regarding the company’s operations, policies, or practices. Following this decision, the board resolved on April 1, 2026 to reduce its size from six to five directors, eliminating the Class III vacancy that will arise at the meeting, and simultaneously appointed Class III director Scott Leftwich to the Audit Committee, signaling a tightened board structure and refreshed committee oversight for shareholders.

These governance changes indicate a modest streamlining of Calidi’s board while maintaining continuity, with the reduction in board size potentially improving decision-making efficiency without reflecting internal conflict. The appointment of Leftwich to the Audit Committee reinforces the company’s focus on audit and financial oversight, developments that may be closely watched by investors and other stakeholders interested in the robustness of its corporate governance framework.

The most recent analyst rating on (CLDI) stock is a Sell with a $0.23 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.

Spark’s Take on CLDI Stock

According to Spark, TipRanks’ AI Analyst, CLDI is a Neutral.

The score is held down primarily by minimal revenue alongside large, persistent losses and cash burn, implying ongoing financing dependence. Technicals are sharply bearish with the stock far below major moving averages (despite oversold readings). Valuation is constrained by negative earnings and no dividend, while recent corporate events are mixed but include notable dilution risk.

To see Spark’s full report on CLDI stock, click here.

More about Calidi Biotherapeutics

Calidi Biotherapeutics, Inc. is a biotechnology company focused on developing therapeutic treatments, operating under a board-driven governance structure typical for its industry. The company’s leadership and committee composition play a key role in overseeing its strategic direction, regulatory compliance, and financial reporting responsibilities.

Average Trading Volume: 239,650

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.64M

For detailed information about CLDI stock, go to TipRanks’ Stock Analysis page.